Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma

a multicenter study

Junichi Shoda, Atsushi Matsuda, Takashi Shida, Masakazu Yamamoto, Masato Nagino, Toshio Tsuyuguchi, Takahiro Yasaka, Susumu Tazuma, Kazuhisa Uchiyama, Michiaki Unno, Nobuaki Ohkohchi, Yasuni Nakanuma, Atsushi Kuno, Hisashi Narimatsu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Wisteria floribunda agglutinin (WFA)-sialylated mucin core polypeptide 1 (MUC1) was investigated as a new glycoprotein marker for cholangiocarcinoma (CC) using glycoproteomics technologies. In this multicenter study, WFA-sialylated MUC1 levels in serum and bile samples were measured to determine their diagnostic capability in biliary tract carcinoma (BTC) and intrahepatic (Ih) CC. Methods: The study included 244 patients with BTC, 59 patients with IhCC, 287 patients with benign biliary tract diseases, and 44 control subjects. Results: Serum WFA-sialylated MUC1 levels were significantly higher in patients with either BTC or IhCC than in control subjects and those with benign biliary tract diseases. Patients with IhCC showed higher WFA-sialylated MUC1 levels than patients with tumors at other sites. No significant differences in WFA-sialylated MUC1 levels were found with regard to cancer stage or tissue type. Receiver operating characteristic curve analysis showed that WFA-sialylated MUC1 was superior to carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) for the diagnosis of benign biliary tract diseases, BTC, and IhCC, as well as for stage I and II carcinomas. Significantly higher levels of biliary WFA-sialylated MUC1 were observed in BTC/IhCC than in benign biliary tract diseases. The diagnostic capability of biliary WFA-sialylated MUC1 was also superior to that of CA19-9, and diagnostic sensitivity was higher than that of biliary cytology for BTC/IhCC. Conclusions: WFA-sialylated MUC1 is a useful novel biomarker for BTC/IhCC. In the future, this measurement should be applied in the clinical setting.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalJournal of Gastroenterology
DOIs
Publication statusAccepted/In press - 2016 Jun 29
Externally publishedYes

Fingerprint

Cholangiocarcinoma
Biliary Tract
Mucins
Multicenter Studies
Biomarkers
Carcinoma
Peptides
Biliary Tract Diseases
Carbohydrates
wisteria lectin
Antigens
Carcinoembryonic Antigen
Serum
Bile
ROC Curve
Cell Biology
Neoplasms
Glycoproteins
Technology

Keywords

  • Biliary tract carcinoma
  • Biomarker
  • Glycoproteomics
  • Intrahepatic cholangiocarcinoma
  • Multicenter study

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma : a multicenter study. / Shoda, Junichi; Matsuda, Atsushi; Shida, Takashi; Yamamoto, Masakazu; Nagino, Masato; Tsuyuguchi, Toshio; Yasaka, Takahiro; Tazuma, Susumu; Uchiyama, Kazuhisa; Unno, Michiaki; Ohkohchi, Nobuaki; Nakanuma, Yasuni; Kuno, Atsushi; Narimatsu, Hisashi.

In: Journal of Gastroenterology, 29.06.2016, p. 1-11.

Research output: Contribution to journalArticle

Shoda, J, Matsuda, A, Shida, T, Yamamoto, M, Nagino, M, Tsuyuguchi, T, Yasaka, T, Tazuma, S, Uchiyama, K, Unno, M, Ohkohchi, N, Nakanuma, Y, Kuno, A & Narimatsu, H 2016, 'Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study', Journal of Gastroenterology, pp. 1-11. https://doi.org/10.1007/s00535-016-1230-0
Shoda, Junichi ; Matsuda, Atsushi ; Shida, Takashi ; Yamamoto, Masakazu ; Nagino, Masato ; Tsuyuguchi, Toshio ; Yasaka, Takahiro ; Tazuma, Susumu ; Uchiyama, Kazuhisa ; Unno, Michiaki ; Ohkohchi, Nobuaki ; Nakanuma, Yasuni ; Kuno, Atsushi ; Narimatsu, Hisashi. / Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma : a multicenter study. In: Journal of Gastroenterology. 2016 ; pp. 1-11.
@article{a81be7e2c98e4b07b916453adc15472b,
title = "Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study",
abstract = "Background: Wisteria floribunda agglutinin (WFA)-sialylated mucin core polypeptide 1 (MUC1) was investigated as a new glycoprotein marker for cholangiocarcinoma (CC) using glycoproteomics technologies. In this multicenter study, WFA-sialylated MUC1 levels in serum and bile samples were measured to determine their diagnostic capability in biliary tract carcinoma (BTC) and intrahepatic (Ih) CC. Methods: The study included 244 patients with BTC, 59 patients with IhCC, 287 patients with benign biliary tract diseases, and 44 control subjects. Results: Serum WFA-sialylated MUC1 levels were significantly higher in patients with either BTC or IhCC than in control subjects and those with benign biliary tract diseases. Patients with IhCC showed higher WFA-sialylated MUC1 levels than patients with tumors at other sites. No significant differences in WFA-sialylated MUC1 levels were found with regard to cancer stage or tissue type. Receiver operating characteristic curve analysis showed that WFA-sialylated MUC1 was superior to carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) for the diagnosis of benign biliary tract diseases, BTC, and IhCC, as well as for stage I and II carcinomas. Significantly higher levels of biliary WFA-sialylated MUC1 were observed in BTC/IhCC than in benign biliary tract diseases. The diagnostic capability of biliary WFA-sialylated MUC1 was also superior to that of CA19-9, and diagnostic sensitivity was higher than that of biliary cytology for BTC/IhCC. Conclusions: WFA-sialylated MUC1 is a useful novel biomarker for BTC/IhCC. In the future, this measurement should be applied in the clinical setting.",
keywords = "Biliary tract carcinoma, Biomarker, Glycoproteomics, Intrahepatic cholangiocarcinoma, Multicenter study",
author = "Junichi Shoda and Atsushi Matsuda and Takashi Shida and Masakazu Yamamoto and Masato Nagino and Toshio Tsuyuguchi and Takahiro Yasaka and Susumu Tazuma and Kazuhisa Uchiyama and Michiaki Unno and Nobuaki Ohkohchi and Yasuni Nakanuma and Atsushi Kuno and Hisashi Narimatsu",
year = "2016",
month = "6",
day = "29",
doi = "10.1007/s00535-016-1230-0",
language = "English",
pages = "1--11",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma

T2 - a multicenter study

AU - Shoda, Junichi

AU - Matsuda, Atsushi

AU - Shida, Takashi

AU - Yamamoto, Masakazu

AU - Nagino, Masato

AU - Tsuyuguchi, Toshio

AU - Yasaka, Takahiro

AU - Tazuma, Susumu

AU - Uchiyama, Kazuhisa

AU - Unno, Michiaki

AU - Ohkohchi, Nobuaki

AU - Nakanuma, Yasuni

AU - Kuno, Atsushi

AU - Narimatsu, Hisashi

PY - 2016/6/29

Y1 - 2016/6/29

N2 - Background: Wisteria floribunda agglutinin (WFA)-sialylated mucin core polypeptide 1 (MUC1) was investigated as a new glycoprotein marker for cholangiocarcinoma (CC) using glycoproteomics technologies. In this multicenter study, WFA-sialylated MUC1 levels in serum and bile samples were measured to determine their diagnostic capability in biliary tract carcinoma (BTC) and intrahepatic (Ih) CC. Methods: The study included 244 patients with BTC, 59 patients with IhCC, 287 patients with benign biliary tract diseases, and 44 control subjects. Results: Serum WFA-sialylated MUC1 levels were significantly higher in patients with either BTC or IhCC than in control subjects and those with benign biliary tract diseases. Patients with IhCC showed higher WFA-sialylated MUC1 levels than patients with tumors at other sites. No significant differences in WFA-sialylated MUC1 levels were found with regard to cancer stage or tissue type. Receiver operating characteristic curve analysis showed that WFA-sialylated MUC1 was superior to carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) for the diagnosis of benign biliary tract diseases, BTC, and IhCC, as well as for stage I and II carcinomas. Significantly higher levels of biliary WFA-sialylated MUC1 were observed in BTC/IhCC than in benign biliary tract diseases. The diagnostic capability of biliary WFA-sialylated MUC1 was also superior to that of CA19-9, and diagnostic sensitivity was higher than that of biliary cytology for BTC/IhCC. Conclusions: WFA-sialylated MUC1 is a useful novel biomarker for BTC/IhCC. In the future, this measurement should be applied in the clinical setting.

AB - Background: Wisteria floribunda agglutinin (WFA)-sialylated mucin core polypeptide 1 (MUC1) was investigated as a new glycoprotein marker for cholangiocarcinoma (CC) using glycoproteomics technologies. In this multicenter study, WFA-sialylated MUC1 levels in serum and bile samples were measured to determine their diagnostic capability in biliary tract carcinoma (BTC) and intrahepatic (Ih) CC. Methods: The study included 244 patients with BTC, 59 patients with IhCC, 287 patients with benign biliary tract diseases, and 44 control subjects. Results: Serum WFA-sialylated MUC1 levels were significantly higher in patients with either BTC or IhCC than in control subjects and those with benign biliary tract diseases. Patients with IhCC showed higher WFA-sialylated MUC1 levels than patients with tumors at other sites. No significant differences in WFA-sialylated MUC1 levels were found with regard to cancer stage or tissue type. Receiver operating characteristic curve analysis showed that WFA-sialylated MUC1 was superior to carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) for the diagnosis of benign biliary tract diseases, BTC, and IhCC, as well as for stage I and II carcinomas. Significantly higher levels of biliary WFA-sialylated MUC1 were observed in BTC/IhCC than in benign biliary tract diseases. The diagnostic capability of biliary WFA-sialylated MUC1 was also superior to that of CA19-9, and diagnostic sensitivity was higher than that of biliary cytology for BTC/IhCC. Conclusions: WFA-sialylated MUC1 is a useful novel biomarker for BTC/IhCC. In the future, this measurement should be applied in the clinical setting.

KW - Biliary tract carcinoma

KW - Biomarker

KW - Glycoproteomics

KW - Intrahepatic cholangiocarcinoma

KW - Multicenter study

UR - http://www.scopus.com/inward/record.url?scp=84976412698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976412698&partnerID=8YFLogxK

U2 - 10.1007/s00535-016-1230-0

DO - 10.1007/s00535-016-1230-0

M3 - Article

SP - 1

EP - 11

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

ER -